Objective: To determine whether subjects suffering from oligoasthenozoospermia would benefit from antioxidant treatment with resveratrol, a natural-occurring polyphenol, and hydrogen sulfide. Methods: A randomized controlled clinical trial involving 54 men with Oligoasthenozoospermia. We randomly assigned resveratrol (n=18), SG 1002 (n=18), and placebo (n=18) for 75 days. Sperm analysis was performed after treatment. Statistical analysis was made with chi square test. Results: When compared to the placebo treated group, SG1002 treatment led to an increase in sperm concentration (11.18 í 106 vs. 17.01 í 106, P < 0.05), sperm motility (10.06 í 106 vs. 20.06 í 106, P<0.05) and motile forms recovery (0.33 í 106 vs. 1.62 í 106, P<0.05). Resveratrol treatment did not significantly affect any of the parameters. Conclusions: SG1002 may reverse oligoasthenozoospermia. It seems to be more potent antioxidant than resveratrol. This findings need be supported by further clinical investigation.